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ABSTRACT 
 Bovine mastitis is the major cause of economic losses in dairy production 
worldwide. Staphylococcus aureus is a major causative agent that possesses 
multiple virulence factors responsible for successful colonization of mammary 
glands. Despite the adoption of current mastitis control measures, S. aureus 
continues to be one of the most prevalent mastitis pathogens throughout the 
world. Lysigin® (Boehringer Ingelheim Vetmedica, Inc, St. Joseph, MO) is a 
commercial S. aureus vaccine currently available in the US and Startvac® (Hipra, 
Girona, Spain) is a commercial S. aureus vaccine in Europe. Although some 
studies evaluated efficacy of these vaccines reported reduction in the duration 
and intensity of clinical signs, none of them prevent S. aureus intramammary 
infection (IMI) in either field trials or under controlled experimental studies. 
Because of the tendency of this organism to cause chronic IMI, treatment with 
antibiotics is of limited success. Therefore, there has been an increasing demand 
for alternative control measures, such as a vaccine to effectively prevent S. 
aureus IMI. The objectives of this study were to evaluate the immune responses 
and protection against S. aureus IMI in dairy cows vaccinated with 
Staphylococcus aureus surface proteins (SASP) and Staphylococcus 
chromogenes surface proteins (SCSP). A total of 18 pregnant Holstein dairy 
cows ranging from heifers to 3rd lactation cows were divided into three groups of 
6 animals each. Animals in Groups 1 and 2 were vaccinated with 1.2 mg/dose of 
SASP and SCSP proteins with Emulsigen-D adjuvant, respectively. Animals in 
Group 3 were injected with PBS mixed with Emulsigen-D at equal proportion (1. 
5 ml each) and used as control. Animals were vaccinated subcutaneously in the 
neck area during late lactation at 28 (D-28) and 14 (D-14) days before drying off, 
and at drying off (D0). Subsequently, each animal was challenged with S. aureus 
strain 60 by teat dipping in bacterial suspension at 107 CFU/ml culture medium. 
Results showed that vaccinated cows had increased milk and serum antibody 
titers and reduced bacterial shedding through milk. Interestingly, SCSP vaccine 
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cross-protected against S. aureus clinical mastitis thus suggesting its potential as 
immunogenic antigens to control bovine S. aureus mastitis. 
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CHAPTER ONE  
LITERATURE REVIEW 
  
 2 
 
INTRODUCTION 
 
Bovine mastitis is one of the most costly diseases of the dairy industry worldwide. 
Mastitis is usually caused by bacterial pathogens. Economic losses due to bovine 
mastitis is estimated to be $2 billion in the United States (NMC, 2005), $400 million in 
Canada (Canadian Bovine Mastitis and Milk Quality Research Network-CBMQRN) and 
$130 million in Australia (Ismail, 2017) per year. These losses are due to decreased 
milk production, decreased milk quality, and the treatment cost of infected animals 
(Petrovski et al., 2006). Mastitis is also a serious public health concern because these 
pathogens or products of these pathogens, have the potential to enter the food supply 
and cause foodborne diseases, especially through the consumption of raw milk (Oliver 
et al., 2005). Guimarães et al. (2017) evaluated the economic impacts of mastitis at the 
herd level from February 2011 to January 2012 on a Holstein dairy herd in tropical 
conditions and found that the cost of mastitis was $61,623.13, with the most prevalent 
components of these losses were due to reduced milk production and milk disposal. 
The economic impact of mastitis on this herd from February 2012 to January 2013 was 
estimated to be $91,552.69 (Guimarães et al., 2017). Overall, at a herd level, the 
component that had the biggest effect on cost of mastitis was the reduction in milk 
production (Guimarães et al., 2017). 
Bovine mastitis can be classified into clinical and subclinical intramammary 
infection (IMI). Clinical mastitis is characterized by visible signs of inflammation 
including udder swelling, redness, heat, pain and change in the consistency (presence 
of clots or flakes) and color of milk. Subclinical mastitis does not show obvious signs of 
inflammation but is manifested by high somatic cell count (SCC) and shedding of 
bacteria through milk. The subclinical mastitis cause greater economic losses because 
the infected cows are not as readily detected and treated or culled (Halasa et al., 2007). 
Bacteria that cause mastitis are usually categorized into environmental or 
contagious mastitis pathogens. This classification depends upon their distribution in 
their natural habitat and mode of transmission from their natural habitat to the mammary 
glands of dairy cows (Calvinho and Oliver, 1998). Environmental bacteria exist in the 
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cow’s environment and can cause infection at any time. The most common mastitis 
causing environmental bacteria include coliform bacteria (Escherichia coli, Klebsiella 
spp., Enterobacter spp. and Citrobacter spp.), environmental Streptococci 
(Streptococcus uberis and Streptococcus dysgalactiae), Trueperella pyogenes, which 
was previously called Arcanobacterium pyogenes or Corynebacterium pyogenes and 
environmental coagulase negative Staphylococcus spp. (CNS) (Staphylococcus 
chromogenes, Staphylococcus simulans, Staphylococcus epidermidis, etc.) (De 
Vliegher et al., 2012). Contagious bacterial pathogens primarily exist on the cow’s teat 
skin and/or infected mammary glands and most commonly spread from infected to non-
infected mammary glands during non-hygienic milking practices. The most frequent 
mastitis causing contagious bacterial pathogens are Staphylococcus aureus, 
Streptococcus agalactiae, Mycoplasma bovis and Corynebacterium bovis (De Vliegher 
et al., 2012). The prevalence of these different bacterial mastitis pathogens varies 
depending on herd management practices, geographical location, and other 
environmental conditions (Oliver and Mitchell, 1984). These different bacterial causative 
agents of mastitis have a multitude of virulence factors that make treatment and 
prevention of mastitis difficult. 
The National Mastitis Council developed a 5-point mastitis control program in 
1969 to control the incidence rate of mastitis. This 5-point mastitis control program 
includes dipping teats in an antiseptic solution before and after milking, proper cleaning 
and maintenance of milking equipment, early detection and treatment of infected 
animals, dry cow therapy with long acting antibiotics to reduce duration of existing 
infection and to prevent new intramammary infection, and finally culling chronically 
infected animals (Blowey and Edmondson, 2010; Neave et al., 1969). Later, it was 
updated to a 10-point plan, which includes more steps such as establishing udder 
health goals, maintain clean, dry and comfortable environment, proper milking 
procedures, proper maintenance and use of milking equipment, good record keeping, 
management of clinical mastitis during lactation, effective dry cow management 
including blanket dry cow therapy, maintenance of good biosecurity for contagious 
pathogens and marketing chronically infected cows, regular monitoring of udder health 
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status and periodic review of mastitis control program (Middleton et al., 2014). Though 
these hygienic milking practices and control measures decrease bacterial spreading, 
transmission, and subsequent infection, it does not fully prevent infections from 
establishing. Dairy farmers utilize antimicrobials as a prophylactic treatment for the 
prevention of mastitis or as therapeutics to treat cases of mastitis (USDA APHIS, 
2008a). 
There has been a growing concern with the extensive use of antimicrobials in 
production animals, especially non-therapeutic usage such as dry cow therapy in the 
case of dairy production, because of potential emergence and spread of antimicrobial 
resistant bacteria. There has been an increased incidence of antimicrobial resistant 
bacteria both in human and animal medical services. Therefore, alternative and 
sustainable control measures such as effective vaccines are required to prevent mastitis 
in dairy cows. Currently, there are two commercial bacterin vaccines, Lysigin® 
(Boehringer Ingelheim Vetmedica, Inc, St. Joseph, MO) in US and Startvac® (Hipra, 
Girona, Spain) in Europe that are claimed to have some effects against S. aureus 
mastitis in dairy cows. These vaccines are bacterin based made up of a suspension of 
killed bacteria (Leitner et al., 2011). In some trials, vaccination with these vaccines were 
reported to decrease production losses, clinical severity, and S. aureus shedding 
(Freick et al., 2016) through milk. Other studies reported that these vaccines had no 
protective effects both under controlled experimental and field studies and also did not 
prevent new IMI (Bradley et al., 2015; Middleton et al., 2009; Middleton et al., 2006; 
Piepers et al., 2017; Schukken et al., 2014). 
MASTITIS 
Mastitis is increasingly becoming a public health concern due to the ability of the 
causative bacterial pathogens and/or their products, such as enterotoxins, to enter the 
food supply and cause foodborne diseases (Hennekinne et al., 2012; Oliver et al., 
2005). The Center for Disease Control (CDC) estimates that roughly 48 million people in 
the United States a year become sick from foodborne diseases (CDC, 2016). 
Foodborne pathogens have been detected in bulk tank milk in multiple studies (Jayarao 
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and Henning, 2001; Oliver et al., 2005; STEELE et al., 1997; Van Kessel et al., 2004). 
These authors found that the number of foodborne pathogens detected in bulk tank milk 
vary with location, management practices, hygiene, and number of animals on the farm 
(Oliver et al., 2005). Similarly, a study on bulk tank milk from east Tennessee and 
southwest Virginia by Rohrbach et al. (1992) showed that 32.5% of the samples 
analyzed contained one or more foodborne pathogens. Even dairy producers who used 
proper hygienic milking practices, pre- and post-milking teat disinfectant and antibiotic 
dry cow therapy, had foodborne pathogens in their bulk tank milk (Jayarao and 
Henning, 2001). The isolation of these foodborne pathogens from bulk tank milk 
samples across the United States demonstrate the threat that mastitis pathogens and 
zoonotic mastitis causing pathogens create on public health if raw milk is consumed or if 
these pathogens make it through processing.  
There are host, pathogen, and environmental risk factors that predispose dairy 
cows to mastitis. The host risk factors include age and parity, stage of lactation, somatic 
cell counts, breed, anatomy of the mammary glands/morphology of udder and teat 
(diameter of teat canal & conformation of udder) and immune-competence (immunity) 
(Sordillo and Streicher, 2002). The environmental risk factors include status of milking 
machine function, udder trauma, sanitation, climate, nutrition, management, season and 
housing condition (Hogan and Smith, 1987). The pathogen risk factors include type, 
number, virulence, frequency of exposure, ability to resist flushing out of the glands by 
milk (adhesion and invasion), zoonotic potential and resistance to antimicrobials 
(Bradley, 2002). The warm, humid, and moist climate favors the growth of bacteria and 
increases the chances of IMI and disease development (Hogan and Smith, 1987). The 
incidence of mastitis varies from farm to farm due to the combined effects of these 
different factors that increase the risk of disease development. Dairy cows are most 
susceptible to IMI during the early dry period and the periparturient period because of 
the absence of hygienic milking procedures during early dry period (Oliver and Mitchell, 
1983) and parturition related immunosuppression and negative energy balance during 
the periparturient period (Drackley, 1999; Esposito et al., 2014). 
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Mastitis can be divided into clinical and subclinical infections. Clinical infections 
are characterized by visible abnormalities in the mammary gland tissue such as 
redness, swelling, pain, increased heat and abnormal changes in milk color and 
consistency (clots or flakes) (Blowey and Edmondson, 2010). Subclinical infections are 
those with nonvisible abnormalities such as a high somatic cell count and shedding of 
causative bacteria (Blowey and Edmondson, 2010). The increase in somatic cell count 
during subclinical infections leads to a decrease in useful components in the milk such 
as lactose and casein (Malek dos Reis et al., 2013). Lactose is the sugar found in milk 
and casein is one of the major proteins in milk and decreases in these two components 
affect quality and quantity of milk yield (Blowey and Edmondson, 2010). During mastitis 
there is an increase in lipase and plasmin, which have a detrimental effect on quantity 
and quality of milk due to the breakdown of milk fat and casein (Blowey and 
Edmondson, 2010). Subclinical infections can reduce milk production by 10 – 12% 
when just one quarter is infected (Akers and Nickerson, 2011). These subclinical 
infections cause some of the greatest unseen economic (Almeida et al., 2015b) losses 
because of their detrimental impact on production and milk quality without showing 
visible signs of infection (Akers and Nickerson, 2011).  
Etiology of mastitis 
The bacterial pathogens that cause mastitis can be classified into environmental 
and contagious pathogens. The environmental bacterial pathogens are organisms that 
can be found anywhere in the cow’s environment and can infect mammary glands at 
any time. Some of the most common environmental mastitis pathogens are coliform 
(bacteria that can utilize lactose) bacteria (E. coli, Klebsiella spp., etc.), environmental 
Streptococci (S. uberis and S. dysgalactiae), Trueperella pyogenes and coagulase 
negative Staphylococcus (CNS) spp. (S. chromogenes, S. haemolyticus, S. epidermidis, 
S. simulans, etc.) (Blowey and Edmondson, 2010; Bradley, 2002; Piessens et al., 
2011). In general, it is believed that mastitis pathogens gain entrance to the teat canal 
during reverse flow of milk due to vacuum pressure fluctuation (Blowey and 
Edmondson, 2010). However, the mechanism of mastitis pathogens colonization in the 
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mammary gland may vary among species of bacteria and the virulence factors 
associated with strains in each species. An example of this is in some cases, it has 
been shown that E. coli has the ability to penetrate the teat canal without the reverse 
flow of milk (Blowey and Edmondson, 2010). Some of the major mastitis pathogens 
such as E. coli (Dogan et al., 2006), Staphylococcus aureus and Streptococcus uberis 
(Almeida et al., 2015a; Almeida et al., 1999; Patel et al., 2009) have ability to adhere to 
and subsequently invade into the mammary epithelial cells. This adherence and 
subsequent invasion ability allows them to persist in the intracellular area and escape 
attack from the host immune defenses and antibiotics (Almeida et al., 2011; Almeida et 
al., 1996; Bayles et al., 1998; Craven and Anderson, 1984; Dogan et al., 2006; Zhao et 
al., 2017). Dogan et al., (2006) compared E. coli strains known to cause chronic 
infections with strains known to cause acute infections and found that chronic strains 
were more invasive to the epithelial cells, leading to the difficulty in clearance and 
persistent infection compared to acute strains. 
Streptococcus uberis is one of the environmental mastitis pathogens that 
accounts for a significant proportion of subclinical and clinical mastitis in lactating and 
non-lactating cows and heifers (Smith et al., 1985). This organism is commonly found in 
the bedding material, which facilitate infection of mammary glands at any time (Bramley, 
1982). S. uberis has various mechanisms of virulence that increases the chances of this 
organism establishing infection. These include a capsule, which avoids phagocytosis, 
adherence to and invasion into mammary epithelial cells (Almeida and Oliver, 1993; 
Oliver et al., 1998). S. uberis adheres to epithelial cells using different mechanisms 
including the formation of pedestals (Matthews et al., 1994) and bridge formation 
through Streptococcus uberis adhesion molecule (SUAM) and lactoferrin (Almeida et 
al., 2015a; Almeida et al., 1999; Patel et al., 2009). This attachment is specific and 
mediated through a bridge formation between Streptococcus uberis adhesion molecule 
(SUAM) (Almeida et al., 2006; Fang and Oliver, 1999) on S. uberis surface and 
lactoferrin which is in the mammary secretion and has a receptor on the mammary 
epithelial surface (Almeida et al., 2015a; Patel et al., 2009). These factors increase the 
pathogenicity of S. uberis to cause mastitis.  
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Staphylococcus chromogenes is another common environmental pathogen that 
is classified as a coagulase-negative Staphylococcus species (CNS) (Bradley, 2002; 
Piessens et al., 2011). This pathogen is most commonly isolated from mammary 
secretions rather than from the environment itself (Gillespie et al., 2009; Piessens et al., 
2011). S. chromogenes consistently isolated from the cow’s udder and teat skin 
(Taponen et al., 2008) and some studies showed that it causes long-lasting, persistent 
subclinical infections (Taponen and Pyörälä, 2009). S. chromogenes, along with other 
CNS species, have been shown to cause subclinical infections in dairy farms that 
reduce the prevalence of contagious mastitis pathogens in their herds (Bradley, 2002). 
The CNS species caused high somatic cell counts in milk on some dairy farms (Fry et 
al., 2014; Gillespie et al., 2009). Woodward et al. (1987) evaluated the normal teat skin 
flora, and found that 25% of the isolates exhibited the ability to prevent growth of some 
mastitis pathogens. An in vitro study conducted on S. chromogenes showed that this 
organism had the ability to inhibit the growth of major mastitis-causing pathogens such 
as S. aureus, S. dysgalactiae, and S. uberis (De Vliegher et al., 2004). In a study 
conducted on conventional and organic Canadian dairy farms, CNS species were found 
in 20% of the clinical samples (Levison et al., 2016). Recently, mastitis caused by CNS 
species increasingly became more problematic in dairy herds (Pyörälä and Taponen, 
2009; Taponen et al., 2008; Taponen et al., 2007; Taponen et al., 2017). However, 
mastitis caused by CNS species is less severe compared to mastitis caused by 
Staphylococcus aureus (Taponen and Pyörälä, 2009). 
Contagious mastitis pathogens, such as Staphylococcus aureus, Streptococcus 
agalactiae, Corynebacterium bovis and Mycoplasma spp., especially M. bovis, are 
organisms that colonize mammary glands of cows or the skin of teat and/or udder. 
These organisms can be transmitted from infected glands or skin to non-infected 
mammary glands of dairy cows (Blowey and Edmondson, 2010) during milking process. 
Both Staphylococcus aureus and Streptococcus agalactiae have strong adhesive 
properties, which allow them to attach to the skin tissue at teat opening and 
progressively grow up through the teat canal (Akers and Nickerson, 2011).  
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Staphylococcus aureus is one of the most common contagious mastitis 
pathogens, with an estimated incidence rate of 43 -74% (Riekerink et al., 2010; USDA 
APHIS, 2008a, 2008b, 2009a, 2014). Staphylococcus aureus is primarily found on the 
skin of the udder of the cow or in the infected mammary glands of a cow. The mode of 
transmission from infected mammary glands and/or colonized udder skin to healthy 
mammary glands is through contact during milking procedures with milker’s hand, towel, 
milking machine (Zadoks et al., 2002). S. aureus usually causes subclinical or chronic 
infections and is difficult to clear with antibiotic treatment (Carter and Kerr, 2003). 
Virulence factors of S. aureus that contribute to its pathogenicity include: protein A, 
exopolysaccharides (capsule, slime, and biofilms) (Donlan and Costerton, 2002; Gotz, 
2002; Otto, 2008; Stewart and Costerton, 2001), adhesion to and invasion into epithelial 
cells (Josse et al., 2017), intracellular survival in macrophages (Fowler et al., 2000) and 
epithelial cells, and production of enterotoxins (Aydin et al., 2011), hemolysins, 
enzymes and super antigens (Kerro-Dego et al., 2012; Kerro and Nederbragt, 2002). 
The ability of this organism to survive within epithelial cells and macrophages allow 
them to avoid detection by the host immune system and resist treatment with antibiotics 
(Almeida et al., 1996). Due to its poor response to treatments, S. aureus infections often 
become chronic with a low cure rate (Abdi et al., 2018). Treatment of Staphylococcus 
aureus mastitis with cloxacillin cured only a 25% of clinical cases and 40% of subclinical 
cases (Tyler and Baggot, 1992). Staphylococcus aureus also has a known ability to 
form biofilms (Donlan and Costerton, 2002; Melchior et al., 2006; Stewart and 
Costerton, 2001) and acquire antimicrobial resistant genes via horizontal resistance 
gene transfer which enables this bacterium to develop antimicrobial resistance 
(Brüssow et al., 2004; Owens et al., 1997). 
The most important virulence factor of S. agalactiae is the capsular 
polysaccharide (Emaneini et al., 2016), which protect this bacterium from being 
engulfed by macrophages and subsequently phagocytosed (Emaneini et al., 2016). 
Another virulence factor of S. agalactiae is the Rib protein, which confers resistance to 
proteases. Emaneini et al. (2016) found that the Rib encoding gene (rib) was detected 
in 89% of the isolates from bovine origin. Streptococcus agalactiae causes persistent 
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infections that usually difficulty to clear without antibiotic treatment (Farnsworth, 1987). 
Though Streptococcus agalactiae is highly contagious, it has good response to 
treatment with antibiotics, which makes it possible to eliminate from herds with current 
mastitis control measures (Tyler and Baggot, 1992). Since the adoption of hygienic 
milking practices, the incidence of mastitis caused by S. agalactiae has dramatically 
decreased and is now rarely observed in dairy herds (Hillerton and Berry, 2003). 
Mastitis caused by Mycoplasma spp. is a growing concern in the United States. It 
is believed that this organism has been underreported due to the difficulty of isolation by 
culture method (Nicholas et al., 2007). The incidence of Mycoplasma mastitis varies 
across the globe, with a 3.2% prevalence rate in the United States that may increase to 
14.4% in a larger herd size of greater than 500 cows (USDA APHIS, 2008a, 2008b, 
2009a, 2014). A risk factor for Mycoplasma mastitis increase with herd size and most of 
the Mycoplasma mastitis cases are subclinical infections with outbreaks linked to 
asymptomatic carriers (Fox, 2012). Pathogenesis of most mycoplasma spp. infection is 
characterized by adherence to and internalization into host cells resulting in colonization 
of the host with immune modulation without causing severe disease (Fox, 2012). 
Mycoplasma species lack a cell wall, thus not sensitive to beta-lactam antibiotics but 
showed sensitivity to non-beta-lactam antibiotics (Jasper, 1981). 
Responses of dairy cows to bacterial intramammary infections 
When the teat canal defenses fail to prevent entry of bacteria, there are several 
udder defenses in place that are characterized as intrinsic defense mechanisms and 
inducible systems (Korhonen et al., 2000). Intrinsic defense mechanisms consist of 
lactoferrin, complement, immunoglobulins, and the cellular immune response. 
Lactoferrin is an intrinsic defense mechanism because its function is to remove iron 
from the milk, which deprives bacteria from receiving this nutrient which is essential for 
bacterial growth (Smith and Oliver, 1981). The complement system is activated in order 
to clear bacteria. This system consists of a series of proteins, which act together, in a 
cascade to kill bacteria by triggering phagocytosis, inflammation, or rupturing the cell 
wall of the bacteria by membrane attack complex (Korhonen et al., 2000). 
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Immunoglobulins mark bacteria by opsonization which is the process by which an 
antibody attaches to the bacteria through its variable chain (fragment), and the other 
constant chain (fragment) portion of the antibody has receptor for phagocytic cells 
(FCγR) that upon binding activates opsonophagocytic killing of a bacterium. These 
phagocytic white blood cells (neutrophils and macrophages), when activated, promote 
phagocytosis of the bacterium. In the process of phagocytosis, the bacteria is engulfed 
and destroyed (Paape et al., 2003). 
One of the functions of immunoglobulins is to work with the complement fraction 
C3b in order to induce phagocytosis of bacteria (Howard et al., 1980; Korhonen et al., 
2000; Targowski, 1983). Various types of cells such as macrophages, 
polymorphonuclear neutrophils (PMNs), and lymphocytes are present in the milk and 
contribute to the intrinsic cellular response. The number of these cells present in the 
milk makes up the somatic cell count (SCC). A high SCC (≥ 200,000 cells/ml) in the 
composite milk of an individual cow serves as an indicator for a possible infection. 
Somatic cells include polymorphonuclear leukocytes (neutrophils, eosinophils, mast 
cells, and basophils), monocytes, macrophages, lymphocytes and some mammary 
epithelial cells (Harmon, 1994). One of the functions of these cells is to recognize 
bacteria and then activate the inducible systems, which will cause a larger and stronger 
host immune response. The inducible systems in the udder consist of the release of 
chemotaxins to attract phagocytic cells and induce an inflammatory response (Rainard 
and Riollet, 2006). When polymorphonuclear neutrophils (PMNs) and macrophages 
phagocytose bacteria, pieces of the destroyed bacteria and then those pieces are 
released. The fragments of bacteria cause the release of chemical mediators, or 
chemotaxins. The release of chemotaxins causes a major influx of PMNs, which is the 
beginning of the inflammatory response (Rainard and Riollet, 2006). 
Immunoglobulins are produced by plasma cells and involved in the clearance of 
pathogens by recognizing and binding specific antigens. The immunoglobulins identified 
in bovine species are IgA, IgM, IgG (subclasses IgG1, IgG2 and IgG3), and a protein 
that has characteristics similar to that of IgE (Butler, 1983; Korhonen et al., 2000). 
Massive selective transport of IgG1 in the mammary gland is one of the unique features 
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of the bovine immune system (Butler, 1983). Both IgG1 and IgG2 are able to fix 
complement, meaning they can activate the complement system, in bovine serum 
(Korhonen et al., 2000; McGuire et al., 1979). Early studies on the role of IgG1 and 
IgG2 antibodies in ruminants showed that polymorphonuclear leukocytes were able to 
phagocytose when these antibodies (McGuire et al., 1979) opsonize the antigen. These 
antibodies play an important role in detecting the presence of microbes and marking 
them for destruction. Though these natural defenses assist in preventing bacteria from 
gaining entry and establishing infection, they are not always fully effective. 
Control and prevention of mastitis 
In the 1960s, the National Institute for Research in Dairying (NIRD) developed a 
five-point plan for mastitis control. These recommendations include treating and 
recording all clinical cases, dipping teats in disinfectants after milking, utilizing dry cow 
therapy at the end of lactation, culling chronic mastitis cases, and maintaining milking 
machine equipment regularly (Middleton et al., 2014). The five-point control program 
later extended to the 10-point control program (Middleton et al., 2014). The additions to 
the five-point plan included establishment of udder health goals, maintaining a clean 
environment, proper milking procedures, good record-keeping, monitoring udder health, 
and periodical review of the mastitis control program (Middleton et al., 2014). The 
presence of contagious or environmental bacterial pathogens of mastitis, is directly 
correlated to the incidence of mastitis. Hygienic practices are important in reducing the 
number of pathogens that cows are exposed to during milking practices. In the parlor, 
hygienic milking practices consist of three different steps: pre-milking cleansing, 
sanitizing milking equipment between uses, and then applying antiseptic solution to the 
teats post-milking (Bushnell, 1984). The pre-milking cleansing step is important to 
prevent environmental bacterial pathogens from gaining entry into intramammary area. 
The other two steps, disinfecting milking equipment between uses and the post-milking 
teat dipping in antiseptic solution, are important to prevent entry of contagious bacterial 
pathogens into intramammary area that can spread from infected to healthy mammary 
glands during milking (Bushnell, 1984). Sometimes even the best control measures do 
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not prevent establishment of infection, therefore farmers rely on antimicrobials for 
prevention as dry cow therapy or as therapeutics to treat cases of mastitis (Saini et al., 
2012a; Saini et al., 2012b). 
As a routine prophylactic mastitis control measure, dairy farmers utilize a blanket 
dry cow antimicrobial therapy in an attempt to prevent bacterial colonization of 
mammary glands during dry period. In the U.S, more than 90% of dairy farms use 
antimicrobials at drying off (USDA APHIS, 2008a). The intramammary infusion of long 
acting antimicrobials at drying off is important to prevent establishment of new 
intramammary infections during dry period and to cure existing chronic and/or 
subclinical infections. 
The most common antibiotics used to treat mastitis include cephalosporin 
(53.2%), followed by lincosamide (19.4%) and non-cephalosporin β-lactam antibiotics 
(19.1%) (USDA APHIS, 2008a). The problem with the use of non-selective blanket 
antimicrobials administration to dairy cows as a prophylactic control of mastitis is that 
they put selective pressure on both mastitis-causing bacteria as well as commensal 
bacteria in the animals’ body (Barber et al., 2003; Barbosa and Levy, 2000). The 
ultimate result may not be different but the exposure level to antibiotics and its 
biotransformed products are different for the bacteria in the gut and in the mammary 
glands during treatment of mastitis. Antibiotics infused into the mammary glands 
excreted through milk and/or enter the serum biotransformed (pharmacokinetics) in the 
liver and/or kidney and excreted from the body through urine or feces into the 
environments. Therefore, both parenteral and intramammary administration of 
antibiotics have significant impact on other commensals or opportunistic bacteria in the 
gastrointestinal tract of dairy cows, some of which are major human pathogens. 
However, the level of exposure to antibiotics seems high for bacteria in the mammary 
glands than bacteria in other parts of the animal body during intramammary infusion of 
antibiotics. This selective pressure can result in antimicrobial resistant bacteria that 
become difficult to clear and persistent on farms and spread among animals (Normanno 
et al., 2007). The antimicrobial resistant bacteria or their genes may spread from these 
sources to human or animals or to other bacteria. McAllister et al., (2001) found that 
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CNS spp. could potentially transfer penicillin, cephalosporin, and fluoroquinolones 
resistant genes to S. aureus. The transfer of these antibiotic resistance genes could 
lead to the development of antimicrobial resistant bacteria including methicillin-resistant 
S. aureus (MRSA) (McAllister et al., 2001). Until recently, MRSA was a common 
antimicrobial resistant strain mainly found in human hospitals; however, recent findings 
indicated that it has also been increasingly isolated from cattle herds (Haran et al., 
2012). The major problem with MRSA is that it is mostly resistant to multiple commonly 
used antimicrobials (multidrug resistant) and difficult to control and eliminate (Holmes 
and Zadoks, 2011). Waller et al. (2011), evaluated the antimicrobial susceptibility of 
CNS species, and found a difference across the species on β-lactamase production. 
Similarly, Sawant et al., (2009) found that 18% and 46% of the S. chromogenes and S. 
epidermidis isolates produce β-lactamase respectively. Sampimon et al. (2009) also 
found a 70% resistance to penicillin in S. epidermidis, but more importantly found that 
30% of the CNS spp. were resistant to more than one antimicrobial. Therefore, in light 
of the foregone it is critically important to develop non-antibiotic feasible and sustainable 
control measures such as vaccines to control staphylococcal infections in animals and 
human. 
Vaccines 
The physiological nature of mammary glands where induced systemic immune 
responses need to cross from the body into the mammary glands, the dilution of effector 
immune responses by large volume of milk coupled with the ability of mastitis causing 
bacteria to develop resistance to antimicrobials makes control of mastitis very difficult. 
Therefore, the development of an alternative preventive tool such as vaccine, which can 
overcome these limitations, has been a crucial focus of current research to decrease 
not only the incidence of mastitis but also the usage of antimicrobials in dairy cattle 
production. Several vaccine studies were conducted over the years as controlled 
experimental and field trials. Some of the most common mastitis pathogens that have 
been targeted for vaccine development are S. aureus, S. agalactiae, S. uberis and E. 
coli (Ismail, 2017). Most of these experimental and some commercial vaccines are 
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bacterins which are inactivated whole organism, and some vaccines contained subunits 
of the organism such as surface proteins, toxins, or polysaccharides. The E. coli 
vaccine studies predominantly used the mutant core antigen J5 for vaccines (Ismail, 
2017). Several studies have been conducted analyzing the efficacy of the commercial 
and experimental vaccines on udder health and protection from mastitis. 
The Startvac® (Hipra, Girona, Spain) is the commercially available vaccine in 
Europe and is a polyvalent vaccine that contains E. coli J5 and S. aureus strain SP140 
(Ismail, 2017). In a field trial, Freick et al. (2016) compared the efficacy of Startvac® with 
Bestvac® (IDT, Dessau-Rosslau, Germany) another herd-specific autologous 
commercial vaccine in a dairy herd with high prevalence of S. aureus and found that the 
herd prevalence of S. aureus mastitis was lower in the Startvac® and Bestvac® 
vaccinated cows compared to the control cows. However, there were no other 
differences in terms of improvement of udder health. These authors (Freick et al., 2016) 
concluded that vaccination with Startvac® and Bestvac®, did not improve udder health. 
In another field efficacy study on Startvac® in the UK, Bradley et al. (2015) found that 
Startvac® vaccinated cows had clinical mastitis with reduced severity and higher milk 
production compared to non-vaccinated control cows (Bradley et al., 2015). Similarly, 
Schukken et al. (2014), evaluated effect of Startvac® on the development of new IMI 
and the duration of infections caused by S. aureus and CNS. These authors (Schukken 
et al., 2014) found that vaccinated cows had decreased incidence rate and a shorter 
duration of S. aureus and CNS mastitis. Piepers et al. (2017), also tested the efficacy of 
Startvac® through vaccination and subsequent challenge with a heterologous killed S. 
aureus strain and found that the inflammatory response in the vaccinated cows was less 
severe compared to the control cows. These authors (Piepers et al., 2017) suggested 
that Startvac® elicited a strong Th2 immune response against S. aureus in vaccinated 
cows and was more effective at clearing bacteria compared to the control cows. 
Contrary to these observations, Landin et al. (2015), evaluated the effects of Startvac® 
on milk production, udder health, and survival on two Swedish dairy herds with S. 
aureus mastitis problems and found no significant differences between the Startvac® 
vaccinated and non-vaccinated control cows on the health parameters they evaluated. 
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An experimental S. aureus vaccine made up of a combination of plasmids 
encoding fibronectin-binding motifs of fibronectin binding protein (FnBP) and clumping 
factor A (ClfA), and plasmid encoding bovine granulocyte-macrophage-colony 
stimulatory factor, was used as vaccine with subsequent challenge with bacteria to test 
its protective effects (Shkreta et al., 2004). These authors (Shkreta et al. 2004), found 
that their experimental vaccine induced immune responses in the heifers that was 
partially protective upon experimental challenge (Shkreta et al., 2004). Another 
controlled experimental vaccine efficacy study was conducted on the slime associated 
antigenic complex (SAAC) which is an extracellular component of Staphylococcus 
aureus, as vaccine antigen in which one group of cows were vaccinated with a vaccine 
containing low amount of SAAC and another group with a high amount of SAAC and 
unvaccinated group served as a control (Prenafeta et al., 2010). Upon intramammary 
infusion (challenge) with S. aureus, no difference in the occurrence of mastitis among all 
three groups despite the fact that the vaccine with high SAAC content induced higher 
production of antibodies compared to the vaccine with low amount of SAAC (Prenafeta 
et al., 2010). Similarly, Pellegrino et al. (2008), vaccinated dairy cows with an avirulent 
mutant strain of S. aureus and subsequently challenged with S. aureus 20 days after 
the second vaccination which resulted in no significant differences in number of somatic 
cell count (SCC) or number of bacteria shedding through milk despite increased IgG 
antibody titer in the vaccinated cows compared to the control cows. 
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CHAPTER TWO IMMUNOLOGICAL RESPONSE OF DAIRY COWS 
VACCINATED WITH STAPHYLOCOCCUS AUREUS SURFACE 
PROTEINS (SASP) AND STAPHYLOCOCCUS CHROMOGENES 
SURFACE PROTEINS (SCSP) AND PROTECTION UPON 
SUBSEQUENT EXPERIMENTAL INTRAMAMMARY CHALLENGE 
(INFECTION)  
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ABSTRACT 
Bovine mastitis is a major cause of economic losses in the dairy industry. One of 
the most prevalent pathogens, Staphylococcus aureus, possesses various virulence 
factors that contribute to its success. Current mastitis control measures have decreased 
incidence of S. aureus mastitis, however, it remains a problem in dairy herds. There are 
two S. aureus vaccines on the market, Lysigin® and Startvac®. These vaccines claim to 
control S. aureus mastitis, however they did not prevent new S. aureus IMI in field trials 
or controlled experimental studies. The objectives of this study were to evaluate the 
immune responses elicited in dairy cows vaccinated with Staphylococcus aureus 
surface proteins (SASP) and Staphylococcus chromogenes surface proteins (SCSP) 
and protection upon subsequent challenge with S. aureus suspension. A total of 18 
Holstein dairy cows were divided into three groups. Group 1 & 2 were vaccinated with 
SASP and SCSP with Emulsigen-D adjuvant respectively. Group 3 was injected with 
PBS mixed with Emulsigen-D and served as a control. Cows were vaccinated at 28 (D-
28) and 14 (D-14) days before drying off, and at dry off (D0). Two weeks after last 
vaccination, each animal was challenged by teat dipping in S. aureus strain 60 culture 
for 14 consecutive days. Milk and serum antibody titers were evaluated during 
vaccination and challenge period. Milk was also evaluated for bacterial shedding and 
somatic cell counts. Out of 5 cows vaccinated with SASP, 2 were infected clinically, 2 
were infected subclinically, and the remaining cow was not infected but shedding low 
number of S. aureus. Out of 6 control cows, 2 were infected clinically and 4 cows were 
infected subclinically. Out of 6 SCSP vaccinated cows there were none infected but 
cows were shedding relatively low number of S. aureus through milk. Statistical analysis 
showed no significant difference (P > 0.05) in clinical frequency among the SCSP, 
SASP, and control groups. The SCSP vaccine cross-protected against S. aureus by 
inducing increased immune response, reducing number of S. aureus shedding in milk 
and decreasing somatic cell counts (SCC), suggesting its potential as an effective 
immunogenic antigens to control bovine S. aureus mastitis. 
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INTRODUCTION 
One of the most costly diseases affecting the dairy industry worldwide is bovine 
mastitis. Bovine mastitis is a disease that is primarily caused by a bacterial infection in 
the mammary gland. Economic losses due to mastitis is roughly $2 billion annually in 
the United States (NMC, 2005). The National Mastitis Council has recommended a 10-
point control program to reduce the rate of mastitis (Middleton et al., 2014). The 
implementation of this program has reduced the incidence rates of mastitis, but it has 
not been successful in preventing new infections from establishing. Dairy farmers in the 
United States and many other parts of the globe rely on the prophylactic intramammary 
infusion of long acting antimicrobials at drying off to prevent new infections during dry 
period or to treat existing infections (USDA APHIS, 2008a). The intramammary 
administration of antimicrobials at drying off is a growing issue since this practice 
exposes large number of healthy animals to antimicrobials. This exposure puts pressure 
on commensal bacteria and other opportunistic bacteria to develop antimicrobial 
resistance. 
Dairy cows are more susceptible to intramammary infection during early dry and 
transition (periparturient) periods. The incidence of IMI is high during early dry period 
because of absence of hygienic milking practices (teat washing and drying, as well as 
pre- and post-milking teat dipping in antiseptic solutions) that are known to reduce teat 
end colonization and infection. The high incidence of mastitis during transition 
(periparturient) period is due to combined effects of parturition hormones causing 
immunosuppression, negative energy balance at early lactation and parturition related 
physical stress (Esposito et al., 2014). In general, immunoglobulins play an important 
role in the host immune system for the clearance of pathogens and fighting off 
infections. In the adaptive immune system, each specific immunoglobulin binds to 
specific epitope on the bacteria that induced its production. This binding triggers 
opsonization, which is an antibody attaches to the antigen (bacteria) to mark it for 
destruction by phagocytic cells (Paape et al., 2003). Immunoglobulin binds to epitopes 
on an antigen through its variable chain and the constant chain end of the 
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immunoglobulin binds to phagocytic cells through specific receptor (FCγR) resulting in 
opsonophagocytic killing of bacteria by phagocytic cells. The most prevalent antibodies 
in bovine serum are IgG (subclasses IgG1 and IgG2), IgA, and IgM (Butler, 1983). The 
immunoglobulin G2 (IgG2) plays an important role in the bovine immune system by 
marking microbes (opsonizing) for destruction and removal by polymorphonuclear 
neutrophils (PMNs) (McGuire et al., 1979). Staphylococcus aureus is one of the most 
frequent pathogens implicated in mastitis (Bradley, 2002). There are two commercial 
vaccines for Staphylococcus aureus mastitis on the market, Lysigin® gin in the United 
States and Startvac® in Europe (Freick et al., 2016). Several field trials and controlled 
experimental studies have been conducted testing the efficacy of Lysigin® and Startvac® 
and results from those studies have shown some results including reduced incidence, 
severity and duration of mastitis in vaccinated cows compared to non-vaccinated control 
cows (Bradley et al., 2015; Piepers et al., 2017; Schukken et al., 2014). Contrary to 
these observations in other studies, these vaccines had no effect on improving udder 
health or showed no difference between vaccinated and non-vaccinated control cows 
(Freick et al., 2016; Landin et al., 2015). None of these bacterin-based vaccines 
prevents new S. aureus IMI (Bradley et al., 2015; Middleton et al., 2009; Middleton et 
al., 2006; Schukken et al., 2014). Therefore, developing an effective vaccine to control 
S. aureus IMI is a sustainable alternative approach for controlling mastitis rather than 
prophylactic use of antibiotics. Differences found in these studies are mainly due to 
methodological differences (vaccination schedule, route of vaccination, challenge 
model, herd size, time of lactation, etc.) in testing the efficacy of these vaccines. It is 
critically important to have a good infection model that mimics natural infection and a 
model that has 100% efficacy in causing infection. Without a good challenge model, the 
results from vaccine efficacy will be inaccurate. 
There are different ways to test the efficacy of experimental vaccines through 
either natural exposure based field studies or controlled experimental studies. 
Experimental intramammary infection of S. aureus can be induced by either 
intramammary infusion of bacteria or teat dipping in bacterial suspension. The 
intramammary infusion of S. aureus is a reliable method in terms of causing infection 
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but it is an unrealistic method in terms of mimicking naturally occurring intramammary 
infections because: 1) large number of bacteria are directly delivered into the 
intramammary area bypassing non-specific natural defenses, as well as inducible innate 
and acquired immune responses, 2) since the host natural and innate defense systems 
were bypassed the host’s acquired immune responses did not get enough time to 
process antigen and deliver protective effector molecules and cells to kill the invading 
pathogen, 3) because of the above mentioned reasons intramammary infusion 
challenge method overwhelms the host innate and acquired immune defenses and is 
not good model for testing vaccine efficacy. Therefore, a challenge model that is closely 
resembles natural infection is necessary to evaluate efficacy of an experimental vaccine 
against S. aureus mastitis. Prior to this vaccine efficacy study, our lab developed 
experimental S. aureus mastitis infection model by teat dipping in S. aureus bacterial 
suspension. This teat dip infection model was utilized in this particular vaccine efficacy 
study. 
Interestingly, our group observed that prior colonization of the mammary gland by 
one strain of S. chromogenes prevented growth and colonization by S. aureus strain 60 
(SAUT2) under in vivo conditions. It is unknown whether this prevention of colonization 
is related to bactericidal/bacteriostatic product from this strain or related to inducible 
innate or acquired immune responses. However, other studies showed that 
bactericidal/static proteins induced strong protective immune response characterized by 
increased production of interferon gamma and IgA in mice (Wang et al., 2017). While 
we were still evaluating bactericidal/static effect of S. chromogenes surface proteins 
(SCSP) and secretory proteins, we thought that these proteins may have similar effect 
seen during mice study elsewhere (Wang et al., 2017). Thus, we decided to further 
evaluate this interesting observation by vaccinating dairy cows with SCSP and evaluate 
protection through experimental challenge. 
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MATERIALS AND METHODS 
Animals 
18 pregnant Holstein dairy cows including 8 heifers of about 23 months (almost 2 
years of age), 6 cows of 1st lactation (about 3 years of age), 3 cows of 2nd lactation 
(about 4 years of age) and 1 cow of 3rd lactation (about 5 years of age) were divided 
into three groups of 6 cows each. Cows in Group 1 (3 cows of 1st lactation, 1 cow of 2nd, 
1 cow of 3rd and 1 heifer) and cows in Group 2 (2 cows of 2nd lactation, 3 cows of 1st 
lactation and 1 heifer) were vaccinated with Staphylococcus aureus surface proteins 
(SASP) and Staphylococcus chromogenes surface proteins (SCSP) with Emulsigen-D 
adjuvant, respectively. Cows in Group 3 (all heifers) were injected with PBS mixed with 
Emulsigen-D (Phibro Animal Health Corporation, Omaha, NE) adjuvant at equal 
proportion (1.5 ml each), and used as control. Prior to enrolment in the study two cows 
(4431 and 4449) had more than 250,000 SCC per mL of milk in all quarters and 4 cows 
had more than 250,000 SCC (4488-LR, 4438-RR, 4420-RR and 4358-LF) per mL of 
milk in one of their four quarters with no bacterial growth from milk. The remaining 
quarters of all cows had less than 250,000 SCC per ml of milk prior to enrolment in the 
study. On average, all animals had a background serum and milk LS mean log titers of 
about 3 to 4. Experimental and control cows were under the same herd management 
throughout the study and housed at the East Tennessee Research and Education 
Center-Little River Animal and Environmental Unit (ETREC-LAEU, Walland, TN). 
Vaccine strain selection, antigen identification and preparation, and vaccine 
formulation 
Staphylococcus aureus surface proteins (SASP) and Staphylococcus 
chromogenes surface proteins (SCSP) were extracted using 1% cholic acid (Sigma 
Aldrich, St. Luis, MO). Staphylococcus aureus strain selection was based on analysis of 
pulsed field gel electrophoresis (PFGE) results of S. aureus isolates from cases of 
bovine mastitis across Tennessee. The criteria for selection was dominance among 
strains or the most frequent isolates among identified PFGE types. One of the dominant 
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strains (S. aureus strain 38 or SAUT1) was selected for SASP vaccine preparation. The 
S. chromogenes strain was selected for SCSP vaccine preparation because of its ability 
to prevent the mammary gland colonization by S. aureus through in vivo inducible 
effects. 
 For antigen preparation, selected strains were streaked on blood agar plates and 
incubated at 37ºC overnight. After incubation, 3 isolated colonies were suspended in 
450 ml of tryptic soy broth (TSB) and grown to mid-log phase with shaking at 125 rpm at 
37ºC in 5% CO2: 95% air balanced incubator, until absorbance of 0.5 nm at OD600 was 
achieved (~ 3 – 4 h of incubation). Then we centrifuged the culture at 500xg for 10 min 
at 4ºC and the pellet was resuspended in 1% cholic acid (Sigma-Aldrich Co) and 
incubated at room temperature for 2 h with shaking (125 rpm). After incubation, 
bacterial suspension was centrifuged at 1000 xg for 30 min at 4oC and proteins in the 
supernatant were concentrated using Centriprep Ultracel-10K YM concentrators with 10 
KDa cut off (EMD Millipore Corporation, Billerica, MA). Protein concentration was 
measured using a BCA protein assay kit (Pierce-Thermofisher Scientific, Waltham, MA). 
Vaccine was prepared, using either SASP or SCSP (1200 µg in 1.5 ml of PBS [pH 7.2]) 
mixed with 1.5 ml of Emulsigen-D, resulting in a total final volume of 3 ml. 
Vaccination schedule 
All cows were given three series of vaccinations at about 14 days interval 
subcutaneously (SQ) on alternate sides of the neck area, approximately midway 
between the base of the ear and the point of the shoulder at 28 days before drying off 
(D-28), 14 days before drying off (D-14) and at drying off (D0) (Table 1). 
Experimental challenge (infection) 
S. aureus strain 60 (SAUT2), which is different from our vaccine strain (S. aureus 
strain 38 or SAUT1), was used as our heterologous challenge strain. This strain was 
originally isolated from a dairy cow with mastitis was another dominant strain frequently 
isolated from different farms(Abdi et al., 2018). An aliquot from a frozen vial of S. aureus 
strain UT60 (SAUT2) stored at -800C in 50% tryptic soy broth / glycerol was inoculated  
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Table 1. Vaccination protocol 
Group # of 
cows 
Vaccine Adjuvant Route Dose Total 
volume 
(ml) 
Frequency 
1 6 SASP Em-D SQ 1.2mg 3  3X at 14 d 
interval at 
D-28, D-14 
& D0 
2 6 SCSP Em-D SQ 1.2 mg 3 “ 
3 6 PBS Em-D SQ 1.5 ml 
PBS + 
1.5 ml 
Em-D 
3  “ 
Legend: SASP = Staphylococcus aureus surface proteins, SCSP = Staphylococcus chromogenes surface 
proteins, EM-D = Emulsigen D, SQ = subcutaneous, D-28 = 28 days before drying off, D-14 = 14 days 
before drying off, D0 = at drying off. 
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to a blood agar plate and grown overnight (23 to 24 h) at 370C. After incubation, five 
colonies were inoculated into 2 liters of tryptic soy broth (TSB) and grown for 3.5 h at 
370C to create our challenge culture. Prior to challenge, teats were cleaned thoroughly 
with a mild non-bactericidal dish detergent and dried with an individual paper towel. 
Each teat was challenged two weeks after dry off by teat dipping in a S. aureus culture 
suspension using a single cup per cow, containing approximately 100 ml of S. aureus 
suspension at 1 x 107 CFU/ml of culture media for approximately 15 sec. The number of 
S. aureus in the challenge suspension was determined using a viable plate count before 
and after the challenge. Each cow was challenged once a day for 14 consecutive days, 
or until removal due clinical mastitis for 3 consecutive days. Challenged teats were 
allowed to air dry for about 10 min prior to releasing cows from the parlor and the floor 
of the parlor was disinfected by bleach at 1:10 dilution. 
Clinical examination of challenged cows 
During the challenge period, rectal temperature, clinical assessment of 
inflammatory changes in the mammary glands tissue, and milk/mammary secretion 
were clinically examined and the findings were recorded by qualified laboratory 
personnel. The following milk scoring system was used to determine severity of 
changes: 0 = Normal, 1 = Flakes, 2 = Clots, 3 = Stringy/watery/bloody (Table 2). 
Inflammatory changes in the mammary glands were scored as follows: 0 = Normal; the 
udder is pliable, no detection of heat, pain, redness, and/or swelling, 1 = Slight swelling; 
the udder is less pliable, some firmness detected, heat, pain, redness, and/or swelling 
not necessarily detected, 2 = Moderate swelling; the udder is firm, redness and heat 
detected, discomfort detected, 3 = Severe swelling; the udder is very hard, red and hot, 
noticeable difference compared to other quarters and the cow exhibits signs of irritation 
(Table 3). 
Rectal temperature of each cow was taken daily during challenge period to 
monitor for potential systemic reactions to challenge with S. aureus. A cow was 
declared to have clinical mastitis when a score of 2 was achieved for both abnormal  
 26 
 
Table 2. Scoring scheme for abnormal changes in milk or dry secretion 
Score Milk or dry secretion appearance 
0 Normal 
1 Flakes 
2 Slugs / clots 
3 Stringy / watery / bloody 
 
Table 3. Scoring scheme for abnormal changes in the mammary gland tissue 
Score Mammary Gland Appearance 
0 Normal; the udder is pliable. Heat, pain, redness, and/or swelling 
are not detectable. Cow exhibits no signs of discomfort. 
1 Slight swelling; the udder is less pliable with some firmness or 
heavier in weight. Redness, heat and pain are generally not 
detectable. 
2 Moderate swelling; the udder is definitely firm, heavy, reddened 
and warm to the touch. The cow generally exhibits signs of 
discomfort (irritable, performs a stepping motion with feet and/or 
kicks) during evaluation. 
3 Severe swelling; the udder is very hard, heavy, red and hot, and 
noticeably larger than other quarters. The cow is extremely 
uncomfortable, very irritable and manifests pain by kicking and 
stepping. 
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inflammatory changes in milk and udder tissue or a score of 3 was achieved either for 
abnormal inflammatory changes in milk or in udder tissue for three consecutive days. 
For a cow in lactation with somatic cell count of ≥200,000 SCC/mL of composite milk 
from quarters or >100,000 SCC/mL of milk from individual quarter and positive isolation 
of the challenge strain from milk during 3 consecutive days, with no clinical signs, we 
declared subclinically infected. For dry cows, these scores are higher because of 
increase in SCC due to decrease in secretion volume. So in this study, SCC of 
≥250,000 cells/ml of milk, with positive isolation of the challenge strain from milk for 3 
consecutive days and no clinical signs, was declared subclinically infected. Clinically 
infected cows were removed from challenge and treated with antibiotics (Ceftiofur 
hydrochloride/Spectramast DC) (Zoetis Inc., Kalamazoo, MI) following manufacturer 
instructions for dry cow treatment. The antibiotic sensitivity patterns of the challenge 
strain 60 (SAUT2) was conducted prior to the beginning of the challenge study during 
challenge model development and the selected challenge strain 60 (SAUT2) was 
sensitive to ceftiofur hydrochloride. The clearance of infection was checked by culturing 
milk samples collected on day of calving (C) and three days after calving (C+3). 
Mammary gland secretion and blood collection 
Mammary gland secretion samples were collected 1 week before the beginning 
of the study (D-35), at 28 and 14 days before drying off (D-28 and D-14) and at drying 
off (D0), and daily during challenge period at days 0 – 7 (Ch0 – Ch+7) and at days 10 
and 14. Individual quarter milk samples collected on day of calving (C) and 3 days after 
calving (C+3) to evaluate presence of S. aureus challenge strain (Table 4). Samples 
were collected aseptically in sterile 15 ml tubes, placed on ice and transported to the 
laboratory. At the lab, mammary gland secretions were placed at – 20oC until 
processed.  
Blood samples were collected 1 week before the beginning of the study (D-35) 
and immediately prior to each vaccination at D-28, D-14, and D0, and then during 
challenge period of days 0 – 7 (Ch0 – Ch+ 7) and on days 10 and 14 (Table 4).  
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Table 4. Sample collection and data recording schedule 
Sample type Group Sample collection time in days 
Blood and mammary secretion 
for antibody titers 
All animals D-35, D-28, D-14, D0, Ch0 - Ch+7, 
Ch+10, Ch+14 
 
Mammary secretion for 
bacteriological culture  
All animals D-28, D-14, D0, Ch0 – Ch+7, Ch+10, 
Ch+14, C0, C+3 and about 2 milk 
samples following antibiotic treatment 
for animals removed due to mastitis 
Mammary secretion for 
somatic cells count (SCC) 
All animals D-28, D-14, D0, Ch0 - Ch+7, Ch+10, 
Ch+14 
Vaccination All animals D-28, D-14, D0 
Rectal temperature 
 
All animals D-29, D-28, D-27, D-26, D-25, D-22, 
D-14, D-13, D-12, D-11, D-7, D0, D+1, 
D+2, D+3, Ch0, Ch+1, Ch+2, Ch+3, 
Ch+4, Ch+5, Ch+6, Ch+7, Ch+8, 
Ch+9, Ch+10, Ch+11, Ch+12, Ch+13, 
Ch+14 
Injection site reaction  All animals D-29, D-28, D-27, D-26, D-25 D-22, 
D-14, D-13, D-12, D-11, D-7, D0, D+1, 
D+2 D+3, D+7, D+14 
Challenge (teats dipping) All animals Ch0 – Ch+13 
Milk score  All animals Ch0 – Ch+14 
Mammary gland score All animals Ch0 – Ch+14 
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Immediately after collection, samples were centrifuged at 2,500 rpm for 20 min at 4ºC 
and serum was separated out and stored at -20ºC until evaluated by ELISA assay. Skim 
milk was prepared from milk or mammary secretion samples by centrifugation at 20, 
000 x g for 30 min to remove fat and cellular debris. Skim samples were stored at -20ºC 
until antibody titers were analyzed by ELISA. 
Milk sample evaluation 
Somatic cell count of milk samples was determined by the Dairy Herd 
Improvement Association Laboratory (Knoxville, TN). Bacteriological analysis were 
conducted following the National Mastitis Council guidelines as described by Oliver et 
al. (Oliver et al., 2004). Briefly, 100 µl of milk was streaked on tryptic soy agar with 5% 
sheep blood (blood agar plates) (Becton, Dickinson and Company, Franklin Lakes, NJ) 
and incubated at 37ºC for 24 h to 48 h until colony growth was observed. Colony 
characteristics such as morphology, color, and hemolysis on blood agar were recorded. 
Those suspected to be Staphylococcus spp. were further tested by gram staining and 
catalase test to differentiate them from Streptococcus spp. The coagulase tube test 
using rabbit plasma was used to differentiate S. aureus from coagulase negative 
staphylococcus (CNS) species. Those which were catalase positive and coagulase 
positive were identified as Staphylococcus aureus. 
Vaccine safety 
In order to monitor for adverse reactions, rectal temperature and injection site 
reaction were measured and recorded. Rectal temperatures were taken 24 h prior to 
vaccination, immediately before vaccination, and for 3 consecutive days following 
vaccination and at days 7 and 14 (Table 4). Injection site reactions were monitored at 
the same time points by measuring the length (cranial/caudal), width (dorsal/ventral), 
and height (thickness) in millimeters (mm). All vaccinated animals were closely 
monitored for loss of appetite or any other complications at 24 h, daily for 1 – 3 days 
and at days 7 and 14 after each vaccination. 
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Evaluation of vaccine induced immune response by ELISA 
Serum- and milk-anti-SASP and -SCSP IgG, IgG1, IgG2, and IgA antibody titers 
were determined using indirect enzyme-linked immunosorbent assay (ELISA) as 
described elsewhere (Kerro Dego et al., 2006). Briefly, 96 well polystyrene plates 
(Immulon® 2 HB) (ThermoScientific, Rochester, NY) were coated with 1 µg/ml of SASP 
or SCSP in a sodium bicarbonate (NaHCO3) coating buffer [1.6 grams sodium 
carbonate (Na2CO3), 2.9 grams sodium bicarbonate (NaHCO3) in a total volume of 1L 
with laboratory grade water and pH adjust to 9.6] and incubated overnight (16 h) at 4ºC. 
The coating buffer was removed and plates were washed 5X using an automated 405 
touch screen (TS) microplate washer (Biotek instrument Inc, Winooski, VT) with PBS 
containing 0.05% tween 20 (v/v) (PBS-T) and blocked with PBS-T containing 1% gelatin 
(W/V) (PBS-TG) for 2 h. The Plates were washed 5X with PBS-T and serum was 
serially diluted four-fold with PBS-TG starting from 1:100 dilution.  
Milk or skim samples were serially four-fold diluted with PBS-TG starting from 
1:10 dilution and incubated for 1h at room temperature. Then plates were washed 5X 
and 100 µl of 1:10,000 diluted (in PBS-TG) horseradish peroxidase-conjugated 
polyclonal sheep anti-bovine IgG or IgA (heavy + Light Chain) or monoclonal sheep 
anti-bovine IgG1 or IgG2 (Bethyl Laboratories, Inc. Montgomery, TX) were added and 
incubated for 1h at room temperature. After incubation, plates were washed 5X with 
PBS-T, and 100 µl of ABTS@ horseradish peroxidase substrate (1 Component, KPL-
SeraCare Life Sciences, Milford, MA) were added and incubated for 20 min at room 
temperature.  
The absorbance was read at wavelength of 405 nm using a Synergy H1 
Microplate reader (Biotek instrument Inc, Winooski, VT). Data was exported to Excel 
(Microsoft Corporation) and the average + 2 standard deviation (avg+2 stdev) of the 
blank row, which received everything except our primary antibody (serum or skim milk), 
were used to determine cutoff point for titer calculation. Serum or skim titers were 
calculated by the intersection of least-square regression of A405 versus logarithm of 
dilution. 
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STATISTICAL ANALYSES 
To assess the effect of SASP and SCSP vaccines on antibody responses, 
antibody impacts on experimental intramammary infection and measures of infection 
post-challenge, a mixed model ANOVA was used (SAS 9.4). Continuous measures 
were assessed using a mixed model ANOVA evaluating the fixed effects of SASP and 
SCSP vaccines (treatments) at certain time points post vaccination (e.g. D-28, D-14, 
D0, Ch0, Ch+1 - Ch+3, Ch+7, & Ch+14), and the interaction of the treatment and day. A 
significant effect was declared when P ≤ 0.05. Multiple comparisons among treatment 
means were evaluated with Fisher’s least significant difference (LSD). To accomplish 
this, linear regression models were conducted within treatment groups to evaluate 
combinations of serum and milk anti-SCSP and -SASP IgG, IgG1, IgG2, and IgA 
antibody titers, somatic cell count (SCC), and S. aureus shedding through milk. 
Regression models were conducted within treatment groups to evaluate the relationship 
among milk and serum antibody titers and 2017 calendar year milk production patterns 
(7 – 47 days in milk (DIM), 47 – 87 DIM, 87 – 127 DIM, milk per day, and peak milk) 
with 2016 milk production added as a covariate. 
To assess the effect of SASP and SCSP vaccines on somatic cell count, S. 
aureus bacterial shedding through milk and infection status during the challenge period, 
a mixed model ANOVA was used (SAS 9.4). Continuous measures were assessed 
using a mixed model ANOVA, evaluating the fixed effects of SASP and SCSP vaccines 
(treatments) at different time points (e.g. D-28, D-14, D0, Ch0, Ch+1 - Ch+3, Ch+7, & 
Ch+14). A significant effect was declared when P ≤ 0.05. Fisher’s exact test was used 
to evaluate the clinical frequency of post challenge infection status. 
RESULTS 
Vaccine safety 
Out of 6 SASP vaccinated cows, one cow was removed from the study and 
euthanized due to physical injury that resulted in permanent lameness. Only five cows 
completed the study in SASP vaccinated group. There were no signs of systemic 
 32 
 
reactions to the vaccine throughout the vaccination period. All vaccinated cows 
developed local reactions at injection sites characterized by slight to moderate swelling. 
There was no significant difference (P > 0.05) in regards to size (mm) of injection site 
reaction among the SASP (39.12 ± 2.20), SCSP (42.46 ± 2.10), and the control (40.24 ± 
2.10) groups. All vaccinated cows had normal rectal body temperature at 24 h prior to 
vaccination, immediately before vaccination and for 3 consecutive days (1 – 3 days) 
after each vaccination and at 7 and 14 days after each vaccination (data not shown). 
Rectal body temperatures were also monitored each day throughout the 14 days of the 
challenging period. There was no significant difference (P > 0.05) in regards to the 
mean rectal temperatures (°F) among the SASP (100.96 ± 0.12), SCSP (100.97 ± 0.12), 
and the control (101.2 ± 0.12) groups. 
Immune responses to vaccines 
Serum anti-SASP IgG2 titers were significantly higher (P < 0.05) in SASP 
vaccinated group compared to control group at D-14, Ch0, and Ch+7 (Fig. 1, panel A). 
There was no significant difference (P > 0.05) in serum anti-SASP IgG2 titers at D-28, 
D0, or Ch+14. Serum anti-SCSP IgG1 titers were significantly higher (P < 0.05) in 
vaccinated group compared to control group at D-14, Ch0, Ch+7 and Ch+14 (Fig. 1, 
panel B). There was no significant difference (P > 0.05) in serum anti-SCSP IgG1 titers 
at D-28 or D0. There was an overall significant difference (P < 0.05) in serum anti-SASP 
IgG1 titers in the vaccinated cows compared to the control cows. There was no 
significant differences (P > 0.05) in serum anti-SASP IgG and IgA. There was no 
significant differences (P > 0.05) in serum anti-SCSP IgG, IgG2, and IgA. There was no 
significant difference in milk anti-SASP antibody titers IgG, IgG1, IgG2, or IgA in the 
vaccinated cows compared to the control cows (P > 0.05). As well as no significant 
difference in milk anti-SCSP antibody titers IgG, IgG1, IgG2, and IgA in the vaccinated 
cows compared to the control cows (P > 0.05). 
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Figure 1. Serum anti-SASP and -SCSP antibody titers. SASP = Staphylococcus aureus surface proteins, 
SCSP = Staphylococcus chromogenes surface proteins, D-28 = 28 days before drying off, D-14 = 14 
days before drying off, D0 = at drying off, Ch = Challenge, Ch0 = right before challenge, Ch+7 = on day 7 
of challenge, Ch+14 = on day 14 of challenge, Ctrl = Control. The different letters represent statistically 
different titers (P < 0.05).  
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Protective effects of SASP and SCSP vaccines 
Of the 5 cows in SASP vaccine group, 2 were infected clinically and another 2 
were infected subclinically and the remaining one cow was neither clinically or 
subclinically infected but shed low number of S. aureus through milk on Ch+1 (Figs. 2 
and 3, Table 8). Of 6 control cows, 2 were infected clinically and the 4 cows were 
infected subclinically (Figs. 2 and 3, Table 8). Out of 6 SCSP vaccinated cows all cows 
were neither clinically nor subclinically infected but they were shedding relatively low 
number of S. aureus through milk during challenge time of 14 days (Figs. 2 and 3, Table 
8). Further evaluation on number of S. aureus shedding through milk and somatic cell 
count (SCC) showed that SASP vaccinated and subclinically infected cows were 
shedding relatively lower number of S. aureus (Fig. 4A) through milk and had lower 
number of somatic cell counts (SCC) (Fig. 4B) compared to control cows (Fig. 5 A&B). 
The SCSP vaccinated cows shed lowest number of S. aureus through milk (Fig. 4C) 
and had lowest number of somatic cell count (SCC) (Fig. 4D) compared to SASP 
vaccinate cows (Fig. 4A&B) and control cows (Fig. 5A&B). However, statistical analysis 
results showed that there were no significant difference (P > 0.05) in the clinical 
frequency among the SCSP (0%), SASP (33.33%), and control (33.33%) groups. 
Overall, there was no significant difference in bacterial shedding in the 
vaccinated cows compared to the control cows over the 14 days of challenge period (P 
> 0.05). However, vaccination of dairy cows at early dry period with SASP or SCSP 
proteins resulted in a relatively lowest S. aureus counts in CFU/ml of milk in SCSP 
vaccinated group followed by lower S. aureus counts in SASP vaccinated group 
compared to the control group that had highest counts during experimental challenge 
period of 14 days (Fig. 3). 
The somatic cell counts from the dry cow secretion is higher than SCC from milk 
of a cow in lactation because of the decrease in volume of fluid in the mammary gland 
during dry period. Therefore, SCC is not good criteria for evaluation of intramammary 
infection in dry cows but infected cows still have relatively higher count compared to 
non-infected cows. There was a significant difference in the somatic cell count (SCC) of  
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Figure 2. Response of cows to S. aureus challenge over the period of 14 days. Staphylococcus aureus 
surface proteins (SASP) vaccinated group, Staphylococcus chromogenes surface proteins (SCSP) 
vaccinated group. 
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Figure 3. Number of S. aureus shedding through milk over 14 days of challenge period. Ch = Challenge 
(infection), SASP = Staphylococcus aureus surface proteins vaccinated group, SCSP = Staphylococcus 
chromogenes surface proteins vaccinated group, Ch+1 – Ch+7 = Day 1 to Day 7 of challenge and at days 
10 and 14 (Ch+10 & Ch+14) of challenge, each symbol on the curve showed mean of S. aureus counts in 
CFU/ml of milk per group per day and P > 0.05. 
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Figure 4. Number of S. aureus shedding through milk/mammary secretion and somatic cell counts (SCC) 
for SASP vaccinated and subclinically infected cows or for SCSP vaccinated cows. Staphylococcus 
aureus counts in mammary secretion from SASP vaccinated and subclinically infected cows (A), somatic 
cell counts (SCC) from SASP vaccinated and subclinically infected cows (B), number of S. aureus counts 
from SCSP vaccinated cows (C) and somatic cell counts (SCC) from SCSP vaccinated cows (D). SASP = 
Staphylococcus aureus surface proteins, SCSP = Staphylococcus chromogenes surface proteins, Ch0 = 
day of challenge, Ch+ 1 – Ch+7, Ch+10 and Ch+14 = Days 1 – 7 of challenge and days 10 and 14 of 
challenge. 
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Figure 5. Number of S. aureus shedding through mammary secretion and somatic cell count (SCC) for 
control cows at certain time points during challenge. (A) Number of Staphylococcus aureus counts on 
days 1 – 7, 10 and 14 of challenge, (B) somatic cell counts (SCC) immediately before challenge (Ch0) 
and on days 6 (Ch+6) and 14 (Ch+14) of challenge. Ctr = Control group.  
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the SASP vaccinated cows and SCSP vaccinated cows compared to the control cows 
(P < 0.05). Somatic cell count (SCC) were relatively higher in subclinically infected 
control cows compared to SASP vaccinated and subclinically infected cows and SCSP 
vaccinated and non-clinically or –subclinically infected cows that were shedding S. 
aureus. Most heifers and few quarters of some cows don’t have enough secretion for 
SCC during the beginning of the study than during the challenge period. Some days 
during challenge, not enough mammary secretion was obtained from some heifers in 
the control group. Because of that, only Ch0, Ch+6 and Ch+14 samples were analyzed 
for SCC. 
The relationship among serum or milk anti-SCSP and –SASP antibody titers and 
number of S. aureus shedding through milk during challenge period 
Evaluation of relationship among number of S. aureus shedding through milk and 
titers showed a significant (P < 0.05) relationship between serum anti-SCSP IgG 
antibody titer and average number of S. aureus shedding in SCSP vaccinated cows 
compared to the control cows. This significance means that without treatment, the 
bacterial shedding would increase, thus the serum anti-SCSP IgG titer kept bacterial 
shedding at a constant level. There were no significant (P > 0.05, data not shown) 
relationship among milk anti-SCSP IgG or serum or milk anti-SCSP IgG1, IgG2 and IgA 
antibody titers of SCSP vaccinated cows and S. aureus shedding through their milk 
during challenge period. Similarly, there were no significant (P > 0.05, data not shown) 
relationship among serum anti-SASP IgA or serum or milk anti-SASP IgG, IgG1, IgG2, 
or IgA antibody titers of SASP vaccinated cows and S. aureus shedding through their 
milk during challenge period (Appendix 1). 
The relationship among anti-SCSP and –SASP antibody titers and somatic cell 
count (SCC) during challenge period 
Significant relationships (P < 0.05) existed among serum anti-SASP IgG, IgG1 
and milk anti-SASP IgG1 titers and somatic cell counts (SCC) of SASP vaccinated cows 
during challenge period. Which means when these serum anti-SASP IgG and IgG1 
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titers and milk anti-SASP IgG1 titers increased, the SCC of those SASP vaccinated 
cows decreased. There were no significant (P > 0.05, data not shown) relationship 
among serum and mammary secretion of anti-SCSP IgG, IgG1, IgG2 and IgA antibody 
titers and somatic cell count (SCC) during challenge period. Similarly, there were no 
significant (P > 0.05) relationship among serum anti-SASP IgG2, IgA and milk anti-
SASP IgG, IgG2 and IgA antibody titers and somatic cell count (SCC) during challenge 
period (Appendix 2).  
The relationship among serum and milk antibody titers and milk production 
status 
For the purpose of this study, milk production was evaluated during 7 – 47 days 
in milk, 47 – 87 days in milk, and 87 – 127 days in milk, milk per day, and peak milk. A 
significant (P < 0.05, Appendix 3) relationship was found between serum anti-SASP 
IgG1 titer at Ch0 and milk production during 7 – 47 DIM in the SASP vaccinated group 
compared to the control group. There were no significant (P > 0.05, data not shown) 
relationship between the milk or serum anti-SASP and anti-SCSP antibody titers at D-28 
and milk production status. 
DISCUSSION 
The goal of this study was to test the protective effects of two experimental S. 
aureus mastitis vaccines through an infection challenge study during early dry period 
and transition (periparturient) period. Proper implementation of current control measures 
have reduced the incidence of mastitis infections but do not prevent new infections from 
establishing. A major problem with the currently available S. aureus commercial 
vaccines (Lysigin® and Startvac®) is their limited to no protective effects in field trials 
and controlled experimental studies (Bradley et al., 2015; Middleton et al., 2009; 
Middleton et al., 2006; Schukken et al., 2014). It was also shown that the vaccination 
with Startvac® (Hippra, Spain) did not have any beneficial effects on udder health, milk 
production, or rate of culling in dairy herds with S. aureus mastitis (Landin et al., 2015).  
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The SASP and SCSP vaccines both induced an increased immune response in the 
vaccinated cows compared to the control cows. There was a significant increase in the 
serum anti-SCSP and anti-SASP IgG1 titers in the vaccinated cows compared to the 
control cows. As well as a significant increase in the serum anti-SASP IgG2 titers in 
vaccinated cows compared to control cows. These findings correspond with findings in 
other studies where there was an overall increase in the serum total antibody titers in 
vaccinated groups compared to non-vaccinated control groups (Gurjar et al., 2013; 
Wilson et al., 2007). Early studies of the role of IgG1 and IgG2 in ruminants show that 
when these antibodies are present, polymorphonuclear leukocytes were able to 
phagocytose antigens effectively (McGuire et al., 1979). With increases in the IgG2 
antibody, there is an increased detection of the presence of microbes to mark them for 
destruction by phagocytic cells. This was indicated with results found in a study 
conducted by Wilson et al. (2007), where there was no clear switch toward IgG1 or IgG2 
dominated responses. However, there was a significant increase in both IgG1 and IgG2 
titers of vaccinated cows over the dry period compared to non-vaccinated control cows 
(Wilson et al., 2007). In the SCSP vaccine group, there were no clinical or subclinical 
infections. With the significant increase in IgG1, the protection from clinical infection 
may be achieved by IgG1 and/or IgG2 mediated opsonophagocytic removal of S. 
aureus from the mammary gland. High background titers were recorded at the starting 
baseline of the study in all cows. This could be due to prior exposure, since the cows in 
this study were not free from exposure to S. aureus or other similar bacterial pathogens 
before this study. However, there were increases in titers from baseline titers after 
vaccination in all vaccinated cows compared to control cows. These results indicate that 
our vaccines did induce an increased immune response in the vaccinated cows. 
The protection efficiency of our two experimental vaccines (SASP and SCSP) was 
tested through teat dip challenge method with S. aureus culture. The teat dip challenge 
model was used to mimic natural infection. Results of this challenge study showed that 
SASP vaccine did not induce protection, since 2 of the 5 cows were clinically infected 
and 2 were subclinically infected. However, the remaining one cow was shedding low 
number of S. aureus in the milk but was not infected clinically or subclinically. Further 
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study with increased number of animals is required to determine the protective effect of 
SASP vaccine. The SCSP vaccinated group was protected from both clinical and 
subclinical intramammary infections. This observation is very interesting and requires 
further evaluation with increased number of animals to confirm these findings. In the 
control group, 2 of the 6 cows were clinically infected and the remaining 4 were 
subclinically infected. These results suggest that the SCSP vaccine is effective at 
controlling S. aureus intramammary infection. 
Bacterial shedding in the SASP and SCSP vaccination groups and control groups 
were not significantly different. However, there was a relatively lower number of S. 
aureus shedding through milk of the vaccinated cows compared to the control cows. 
Even more so, between the two vaccination groups, the SCSP vaccinated cows had 
lower bacterial shedding throughout the challenge period compared to the SASP 
vaccinated cows. These results showed that the SCSP vaccine was better at reducing 
S. aureus shedding than the SASP vaccine as well as control group. Low number of S. 
aureus shedding throughout the challenging period, without increase in somatic cell 
count may be due to daily challenge with S. aureus. This bacteria could have been 
unable to colonize glands and removed with milk rather than establishing infection, in 
which S. aureus is growing and multiplying inside the mammary gland. Monitoring cows 
over longer period of time after challenge period before treating them with antibiotics 
would clarify this findings. 
This study was conducted during the dry period, which resulted in a relatively 
increased SCC due to decreased volume of secretion samples. Some of the cows 
enrolled in this study were heifers, which made it even more difficult to collect enough 
sample for SCC. Due to this, enough sample for SCC in the control group was only 
collected on Ch0, Ch+6, and Ch+14. There was lower SCC in the SASP and SCSP 
vaccinated group compared to control group. The SCC of the cows that were 
categorized as subclinically infected in the SASP vaccination group was compared to 
the SCC of all the cows in SCSP vaccination, since none were clinically or subclinically 
infected, and there was a relatively lower SCC in the SCSP vaccination group. A meta-
analysis conducted by Djabri et al. (2002), found that SCC for S. aureus infections were 
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roughly 357,000 cells/ml and for CNS infections were roughly 138,000 cells/ml. The 
results from Djabri et al. (2002) showed that overall, S. aureus infection caused a 
greater increase in SCC compared to CNS infections. In contradiction, Sharma et al. 
(2011), found that both S. aureus and S. chromogenes had relatively similar increase in 
SCC compared to other species. The high SCC during the dry period, the differences in 
parity (Sharma et al., 2011) of the cows enrolled in this study, and/or the infection status 
all contributed to increased SCC and differences of SCC in the treatment groups. So 
use of cows in the same parity would aide in avoiding this possibility. 
Further analysis on the relationship between the serum and milk antibody titers with 
bacterial shedding showed that increases in serum anti-SCSP IgG antibody titer kept 
the S. aureus shedding at a constant level and that without treatment, the bacterial 
shedding numbers would increase. This could indicate that IgG play a role in reducing 
S. aureus bacterial shedding. Overall, there were no significant differences among 
treatment groups for either IgG or IgA, and there was no significant difference in S. 
aureus shedding. However, this relationship showed that IgG antibody plays a role in 
lowering the bacterial shedding in the mammary gland. 
Furthermore, the relationship between antibody titers and SCC was analyzed. 
Significant relationships were found in serum anti-SASP IgG and IgG1, titers. This 
relationship represents that when these antibody titers increased, the SCC decreased. 
Interestingly, there was no relationship found with anti-SCSP antibody titers and SCC. 
However, this vaccine group had no clinical or subclinical infections. However, as 
indicated previously, the use of SCC as a measurement for IMI for dry cows is 
problematic since SCC already high due to reduction in secretion volume. Though there 
were increased immune responses in both vaccination groups, there was little 
correlation of the increased immune responses with decreasing SCC.  
The relationship between antibody titers and milk production was analyzed to see 
whether our vaccines had any effect on milk production following this study. For this 
analysis we used milk produced at 7 - 47 days in milk, 47 - 87 days in milk, and 87-127 
days in milk, milk per day, and peak milk. With an increase in serum anti-SASP IgG1 
antibody titer, there was a decrease in milk production at 7- 47 days in milk. In regards 
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to the SCSP vaccine, there was neither an increase nor decrease in milk production 
during those time points. This means the immune responses induced by this vaccine did 
not have a negative impact on the milk production. Further detail study over longer 
period of time is required to determine conclusive findings on this observation. 
CONCLUSION 
In conclusion we observed that three consecutive vaccinations of dairy cows at 
28 and 14 days before drying off, and at drying of with SASP and SCSP induced a 
significant increase in immune responses in vaccinated cows compared to control cows. 
The subsequent experimental challenge of vaccinated cows with the heterologous strain 
of S. aureus resulted in reduced number of bacterial shedding in milk in vaccinated 
cows compared to control cows. More interestingly, SCSP vaccine cross-protected 
vaccinated cows from S. aureus mastitis indicating that SCSP seems to perform better 
than SASP as a vaccine to control Staphylococcus aureus mastitis in dairy cows. 
Further detailed studies using different antigen doses (antigen dose titration) with 
different adjuvants, routes of vaccination coupled with monitoring of duration of 
immunity while evaluating efficacy by natural exposure may optimize the efficacy of 
SCSP vaccine to control S. aureus mastitis. 
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Appendix 1. Mammary secretion and mammary gland tissue physical clinical examination results during 
challenge 
VG CID  Q Milk/mammary secretion score Mammary gland score Infection status  
   Ch
0 
Ch
1 
Ch
2 
Ch3 Ch
4 
Ch
5 
Ch
6 
Ch
0 
Ch
1 
Ch
2 
Ch
3 
Ch
4 
Ch
5 
Ch
6 
 
SASP 4358 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCM & shedding 
large number of S. 
aureus from ch1 – 
ch6 
RR 0 0 0 0 0 0 1 0 0 0 0 1 0 0 
LR 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4431 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCM & shedding 
S. aureus on ch2 & 
Ch6 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4493 RF 0 0 0 0 0 0 0 0 0 1 1 0 0 0 Not infected but 
shedding low No. 
of S. aureus on 
ch1 
RR 0 0 0 0 0 0 0 0 0 1 1 0 0 2 
LR 0 0 0 0 0 0 0 0 0 1 1 0 0 3 
LF 0 0 0 0 0 0 0 0 0 1 1 0 0 3 
4488 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Developed CM 
and shedding large 
No. of S. aureus 
and treated 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 2 3 3 3 Rx  0 2 3 3 3 Rx  
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4592 RF 0 2 0 1 1 1  0 0 0 0 0 0 0 Developed CM & 
shedding large No. 
of S. aureus on 
Ch5 & Ch6 and 
treated 
RR 0 0 0 0 0 0  0 0 0 0 1 2 3 
RX 
LR 0 0 0 0 0 0  0 0 0 0 3 3 3 
Rx 
LF 0 2 0 1 0 1  0 0 1 0 0 0 0 
SCSP 4420 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No mastitis but 
shedding large No. 
of S. aureus on 
Ch2 and then very 
low S. aureus on 
ch4, 5 & 6 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4438 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No mastitis but 
shedding low No. 
of S. aureus on 
Ch5 & Ch6  
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4449 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No mastitis but 
shedding very low 
No. of S. aureus 
on Ch3, 4 & 6. 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4519 RF 0 0 0 0 0 0 0 0 0 0 0 1 0 1 No mastitis but 
shedding large No. 
of S. aureus on 
Ch1 and then very 
low number on 
ch3, 4, 5 & 6. 
RR 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
4521 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No mastitis but 
shedding Low No. 
of S. aureus on 
ch2, 4, 5 & 6. 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4610 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No Mastitis but 
shedding large No. 
of S. aureus on 
Ch3 and then very 
low S. aureus on 
Ch4 & 6 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Control 4579 RF 0 3 3 3  3R
x 
  0 3 3 3 3R
x 
  Developed 
CM and shedding 
large No. of S. 
aureus from ch1 -
Ch4 and treated 
RR 0 0 0 0 0   0 0 0 0 0   
LR 0 0 0 0 0   0 0 0 0 0   
LF 0 0 0 0 0   0 0 0 0 0   
4604 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Developed CM 
and shedding S. 
aureus on Ch1 -3, 
5 and 6. large No. 
of S. aureus on 
Ch2, 5 & 6 and 
treated 
RR 0 0 0 0 0 2 0 0 0 0 0 0 2 3 
Rx 
LR 0 0 0 0 0 2 0 0 0 0 0 0 2 3 
Rx 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 3 
Rx 
4608 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCM and shedding 
S. aureus from 
Ch2 – Ch6 
RR 0 0 0 0 0 0 0 0 0 0 0 1 1 1 
LR 0 0 0 0 0 0 0 0 0 0 0 1 1 1 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4612 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCM and shedding 
few S. aureus on 
ch1 and large no. 
S. aureus on Ch2 
& Ch6 
RR 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
LR 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4619 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 1 SCM and shedding 
large No. of S. 
aureus from Ch1 –
Ch6. 
RR 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
LR 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
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4620 RF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SCM and shedding 
large No. of S. 
aureus from Ch1 – 
Ch6 
RR 0 0 0 0 0 0 1 0 0 0 0 0 1 2 
LR 0 0 0 1 1 0 0 0 0 0 0 0 1 1 
LF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Legends: V = vaccine, CID = Cow ID, QR = Quarter, SASP = Staphylococcus aureus surface proteins, 
SCSP = Staphylococcus chromogenes surface proteins, Ch = Challenge, Ch0 = day of challenge, Ch1 – 
Ch6 = Day 1 – Day 6 of challenge, SCM = Subclinical mastitis, CM = Clinical mastitis, Ctrl = Control, RF = 
Right front, RR = Right rear, LR = Left rear, LF = Left front, 0 = normal, 1 = mild changes, 2 = moderate 
change, 3 = Severe changes. 
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Appendix 2. Rectal body temperature during challenge 
V CID Rectal body temperature  
  P-Ch Ch0 Ch1 Ch2 Ch3 Ch4 Ch5 Ch6 Ch7 Ch8 Ch9 Ch10 Ch11 Ch12 Ch13 Ch14 
SASP 4358 101.3 100.5 101.4 100.7 100.4 99.1 100.1 100.2 100.7 100.4 100.6 99.1 100.2 100.4 99.7 98.1 
4431 100.1 100.2 100.4 101.6 100.7 100.7 100.9 100.4 100.4 100.8 100.7 100.2 99.9 100.5 99.6 99.7 
4493 101.9 100.7 101.0 101.8 101.1 101.3 100.7 101.1 101.3 101.4 101.4 100.5 100.5 101.1 100.2 100.9 
4488 100.8 101.5 101.6 102.1 101.0 101.2 100.9 100.9 101.0 101.5 100.8 100.7 101.5 101.6 101.1 99.8 
4592 102.5 100.6 101.4 101.3 100.5 100.7 100.9 100.8 100.8 100.9 100.8 99.6 100.9 100.9 100.8 100.3 
SCSP 4420 100.7 100.5 101.2 101.1 99.6 100.2 100.5 100.2 100.5 100.3 100.9 100.4 99.7 99.0 99.0 100.2 
4438 100.6 100.2 101.1 101.8 100.4 100.4 100.3 101.0 101.0 101.2 100.5 99.9 98.7 100.2 98.0 100.2 
4449 101.0 101.4 101.2 101.7 101.2 100.5 100.4 101.2 101.4 101.0 101.3 100.8 100.7 100.4 99.8 100.6 
4519 101.7 101.1 101.7 101.8 101.3 100.9 101.2 101.1 101.5 101.0 101.3 100.3 100.2 101.1 100.6 101.3 
4521 100.9 100.5 101.5 101.5 100.2 100.7 100.2 100.9 100.9 100.5 100.4 99.5 100.5 99.7 100.2 100.2 
4610 101.5 101.3 101.8 102.0 101.1 101.5 101.2 101.3 101.3 101.6 101.0 101.4 100.6 100.8 101.1 100.7 
Ctrl 4579 101.4 101.1 101.3 101.8 101.1 100.7 99.5 101.0 101.0 100.9 101.1 100.5 100.8 100.9 101.4 100.9 
4604 101.3 101.3 101.1 102.2 100.8 101.2 101.0 101.2 100.9 101.2 101.2 100.4 101.0 100.6 100.7 101.2 
4608 101.2 101.2 101.2 101.8 101.0 101.2 101.1 101.1 101.0 101.0 101.1 100.9 100.7 101.0 100.9 99.7 
4612 101.5 101.2 101.4 101.8 100.8 101.1 100.4 100.8 100.9 101.0 101.0 101.1 100.9 100.7 100.6 101.3 
4619 101.3 100.3 101.2 100.8 101.1 100.5 100.4 100.5 100.5 100.9 100.6 100.0 100.3 100.6 100.4 100.6 
4620 100.7 100.9 101.3 101.8 100.3 100.2 100.5 101.0 101.0 101.4 100.9 101.9 99.4 100.6 99.8 100.6 
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Appendix 3. The relationship among serum or milk anti-SCSP and –SASP antibody titers and number of 
S. aureus shedding through milk during challenge period 
DepVar RegVar Control Slope Trt Slope Slopes 
differ p-
value 
Shedding_AVG ssa_igG -354 (1655) SASP -3981 (2504) 0.24 
Shedding_AVG scns_igG 3183* (1154) SCSP -614 (1406) 0.04* 
Shedding_AVG ssa_igG1 -648 (899) SASP -1667 (6396) 0.88 
Shedding_AVG scns_igG1 -1952 (1728) SCSP 142 (721) 0.27 
Shedding_AVG ssa_igG2 -522 (1220) SASP 804 (3028) 0.69 
Shedding_AVG scns_igG2 441 (373) SCSP -892 (1163) 0.28 
Shedding_AVG ssa_igA 1341 (1316) SASP -4894 (3058) 0.07 
Shedding_AVG scns_igA 2103 (1353) SCSP 1880 (2670) 0.94 
Shedding_AVG msa_igG -2808 (3423) SASP -1647 (9266) 0.91 
Shedding_AVG mcns_igG -1273 (3835) SCSP -1327 (2690) 0.99 
Shedding_AVG msa_igG1 -3240 (5562) SASP 3537 (15535) 0.68 
Shedding_AVG mcns_igG1 -10613 (40703) SCSP 555 (3653) 0.79 
Shedding_AVG msa_igG2 1413 (4388) SASP -354 (3679) 0.76 
Shedding_AVG mcns_igG2 1105 (1220) SCSP -1197 (2419) 0.4 
Shedding_AVG msa_igA 1507* (638) SASP -3862 (2293) 0.03* 
Shedding_AVG mcns_igA 1171 (1409) SCSP 1314 (2432) 0.96 
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Appendix 4. The relationship among anti-SCSP and –SASP antibody titers and somatic cell (SCC) during 
challenge period 
DepVar RegVar Control Slope Trt Slope Slopes differ  
p-value 
log_SCC ssa_igG 0.990 (0.741) SASP -1.32 (0.703) 0.03* 
log_SCC scns_igG 0.149 (0.960) SCSP -0.477 (1.22) 0.69 
log_SCC ssa_igG1 -0.053 (0.406) SASP -1.48* (0.497) 0.03* 
log_SCC scns_igG1 -0.591 (1.02) SCSP 0.628* (0.312) 0.25 
log_SCC ssa_igG2 -0.411 (0.537) SASP 0.105 (0.656) 0.54 
log_SCC scns_igG2 0.103 (0.226) SCSP -0.071 (0.479) 0.74 
log_SCC ssa_igA 0.663 (0.729) SASP 0.070 (0.535) 0.51 
log_SCC scns_igA 1.30 (0.778) SCSP 1.64 (0.896) 0.78 
log_SCC msa_igG -0.003 (1.29) SASP 2.36 (1.74) 0.28 
log_SCC mcns_igG -1.39 (1.85) SCSP 0.206 (1.09) 0.46 
log_SCC msa_igG1 -3.33* (1.13) SASP 1.77 (1.00) 0.001* 
log_SCC mcns_igG1 1.50 (20.6) SCSP 1.31 (1.43) 0.99 
log_SCC msa_igG2 -0.160 (1.56) SASP -1.32* (0.503) 0.48 
log_SCC mcns_igG2 -0.104 (0.612) SCSP 1.23 (0.966) 0.25 
log_SCC msa_igA 0.471 (0.275) SASP -0.346 (0.663) 0.26 
log_SCC mcns_igA -0.248 (0.719) SCSP 0.726 (1.02) 0.44 
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Appendix 5. The relationship between serum antibody titers at Ch0 and milk production status 
DepVar RegVar Control Slope Trt Slope Slopes 
differ p-
value 
7 – 47 DIM ssa_igG 23.95 (50.53) SASP 9.55 (73.66) 0.822 
7 – 47 DIM scns_igG -20.94 (23.43) SCSP 13.46 (18.49) 0.332 
7 – 47 DIM ssa_igG1 16.55 (6.71) SASP -90.36* (20.95) 0.017* 
7 – 47 DIM scns_igG1 -9.23 (23.67) SCSP 12.34 (19.97) 0.536 
7 – 47 DIM ssa_igG2 22.59 (19.37) SASP 30.74 (26.44) 0.82 
7 – 47 DIM scns_igG2 -3.14 (4.95) SCSP 22.76 (18.34) 0.266 
7 – 47 DIM ssa_igA 7.66 (17.24) SASP -30.56 (57.72) 0.571 
7 – 47 DIM scns_igA 21.05 (86.39) SCSP -15.07 (40.29) 0.73 
47 – 87 DIM ssa_igG 21.95 (51.48) SASP 14.10 (85.70) 0.942 
47 – 87 DIM scns_igG 13.18 (26.68) SCSP -8.92 (33.04) 0.639 
47 – 87 DIM ssa_igG1 26.95 (10.10) SASP -53.86 (34.58) 0.111 
47 – 87 DIM scns_igG1 -4.75 (32.14) SCSP 5.33 (28.58) 0.83 
47 – 87 DIM ssa_igG2 31.17 (20.26) SASP 0.424 (27.22) 0.432 
47 – 87 DIM scns_igG2 -6.74 (6.14) SCSP 18.24 (19.01) 0.3 
47 – 87 DIM ssa_igA 6.41 (17.97) SASP 23.76 (58.96) 0.797 
47 – 87 DIM scns_igA -0.876 (107.23) SCSP -28.81 (51.67) 0.83 
87 – 127 DIM ssa_igG 6.14 (38.40) SASP -68.39 (52.55) 0.335 
87 – 127 DIM scns_igG 4.88 (26.40) SCSP 5.58 (31.90) 0.988 
87 – 127 DIM ssa_igG1 24.08 (11.14) SASP -26.03 (29.65) 0.212 
87 – 127 DIM scns_igG1 3.86 (30.66) SCSP -4.57 (30.08) 0.857 
87 – 127 DIM ssa_igG2 23.40 (20.36) SASP -3.88 (23.55) 0.445 
87 – 127 DIM scns_igG2 -7.30 (5.06) SCSP 19.81 (15.04) 0.186 
87 – 127 DIM ssa_igA 0.938 (14.78) SASP 47.19 (47.74) 0.423 
87 – 127 DIM scns_igA -28.52 (85.72) SCSP -69.66 (55.49) 0.714 
Milk per day ssa_igG 17.60 (36.07) SASP -25.50 (45.02) 0.509 
Milk per day scns_igG 10.55 (19.64) SCSP -18.87 (27.39) 0.447 
Milk per day ssa_igG1 21.36* (6.63) SASP -27.97 (17.73) 0.08 
Milk per day scns_igG1 -3.89 (24.49) SCSP 12.24 (26.45) 0.685 
Milk per day ssa_igG2 24.76 (11.34) SASP 14.77 (11.81) 0.584 
Milk per day scns_igG2 -5.32 (4.84) SCSP 15.26 (16.42) 0.316 
Milk per day ssa_igA 5.15 (13.16) SASP 19.59 (45.03) 0.778 
Milk per day scns_igA -0.268 (83.10) SCSP -34.44 (55.08) 0.754 
Peak milk ssa_igG 25.07 (43.70) SASP -16.09 (68.96) 0.649 
Peak milk scns_igG 14.57 (20.45) SCSP -14.17 (25.68) 0.446 
Peak milk ssa_igG1 24.13* (7.36) SASP -58.86 (28.67) 0.068 
Peak milk scns_igG1 -7.52 (26.10) SCSP 4.89 (22.07) 0.741 
Peak milk ssa_igG2 29.69 (15.82) SASP -8.23 (20.19) 0.236 
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Peak milk scns_igG2 -5.52 (5.25) SCSP 15.94 (20.14) 0.378 
Peak milk ssa_igA 7.67 (15.76) SASP -6.52 (53.51) 0.816 
Peak milk scns_igA 10.39 (89.85) SCSP -17.15 (41.33) 0.799 
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Appendix 6. Relationship between milk antibody titers at Ch0 and milk production status during time 
period following experimental vaccination and challenge 
DepVar RegVar Control Slope Trt Slope Slopes 
differ p-
value 
7 – 47 DIM msa_igG 24.80 (11.84) SASP -79.80 (39.49) 0.127 
7 – 47 DIM mcns_igG -156.3 (150.08) SCSP -48.53 (36.58) 0.536 
7 – 47 DIM msa_igG1 -9.06 (150.41) SASP 89.18 (118.33) 0.659 
7 – 47 DIM mcns_igG1 -440.64 (461.21) SCSP -4.95 (35.42) 0.416 
7 – 47 DIM msa_igG2 -41.25 (16.95) SASP 21.22 (13.45) 0.102 
7 – 47 DIM mcns_igG2 0.028 (21.47) SCSP 19.77 (35.65) 0.668 
7 – 47 DIM msa_igA -4.83 (8.08) SASP -88.70 (67.20) 0.341 
7 – 47 DIM mcns_igA -37.70 (22.69) SCSP 13.40 (24.57) 0.262 
47 – 87 DIM msa_igG 41.92 (10.06) SASP -118.56 (34.01) 0.046* 
47 – 87 DIM mcns_igG -176.03 (228.56) SCSP -28.18 (43.23) 0.57 
47 – 87 DIM msa_igG1 -75.77 (209.72) SASP 152.11 (176.56) 0.493 
47 – 87 DIM mcns_igG1 -530.09 (590.01) SCSP 12.89 (83.20) 0.429 
47 – 87 DIM msa_igG2 -62.42 (27.15) SASP 24.56 (19.87) 0.123 
47 – 87 DIM mcns_igG2 -8.26 (28.03) SCSP 2.73 (37.64) 0.83 
47 – 87 DIM msa_igA -11.06 (12.71) SASP -71.10 (77.66) 0.525 
47 – 87 DIM mcns_igA -47.85 (26.60) SCSP 0.021 (26.73) 0.294 
87 – 127 DIM msa_igG 38.66 (12.00) SASP -71.77 (28.37) 0.07 
87 – 127 DIM mcns_igG -95.28 (244.62) SCSP -5.00 (34.00) 0.739 
87 – 127 DIM msa_igG1 -115.84 (153.17) SASP 138.94 (98.40) 0.297 
87 – 127 DIM mcns_igG1 -325.57 (488.97) SCSP 197.77 (156.21) 0.383 
87 – 127 DIM msa_igG2 -52.00 (35.92) SASP 9.45 (22.79) 0.285 
87 – 127 DIM mcns_igG2 -13.94 (25.80) SCSP -6.20 (63.38) 0.917 
87 – 127 DIM msa_igA -12.40 (10.55) SASP -21.31 (20.82) 0.739 
87 – 127 DIM mcns_igA -38.48 (27.61) SCSP -14.1 (26.04) 0.566 
Milk per day msa_igG 33.20 (9.25) SASP -95.65 (75.11) 0.069 
Milk per day mcns_igG -140.43 (177.47) SCSP -19.17 (27.85) 0.548 
Milk per day msa_igG1 -59.29 (164.97) SASP 76.03 (110.86) 0.566 
Milk per day mcns_igG1 -422.28 (455.18) SCSP -15.48 (49.13) 0.44 
Milk per day msa_igG2 -49.52 (12.94) SASP 19.82 (8.79) 0.047* 
Milk per day mcns_igG2 -6.45 (19.64) SCSP 48.46 (55.31) 0.419 
Milk per day msa_igA -8.72 (8.58) SASP -17.28 (14.69) 0.665 
Milk per day mcns_igA -37.98 (19.82) SCSP 11.23 (23.00) 0.203 
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Peak milk msa_igG 37.03 (15.46) SASP -95.65 (75.11) 0.226 
Peak milk mcns_igG -182.53 (160.39) SCSP -46.37 (42.02) 0.472 
Peak milk msa_igG1 -48.41 (175.95) SASP 164.87 (185.74) 0.492 
Peak milk mcns_igG1 -534.10 (430.66) SCSP -18.85 (33.30) 0.319 
Peak milk msa_igG2 -57.39 (24.75) SASP -5.12 (20.09) 0.243 
Peak milk mcns_igG2 -4.75 (21.65) SCSP 21.19 (31.49) 0.546 
Peak milk msa_igA -8.88 (11.17) SASP 77.08 (96.71) 0.47 
Peak milk mcns_igA -44.44 (17.44) SCSP 9.89 (18.81) 0.124 
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